|
Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study analysed the prognostic impact of EGFR family expression in endometrial cancer in relation to PI3K-AKT and MAPK-ERK signalling, as well as drug sensitivity.
|
20664599 |
2010 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations.
|
24995579 |
2014 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PI3K/AKT/mTOR pathway is frequently overactivated in endometrial cancer (EC).
|
30853360 |
2019 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in endometrial cancer (EC).
|
25624430 |
2015 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, HOTAIR activated the PI3K/Akt pathway to promote EC progression by suppressing PTEN <i>in vivo</i> Taking these results together, we revealed that high expression of HOTAIR promoted cell proliferation and inhibited apoptosis through activating the PI3K/Akt pathway via binding to PTEN, which might provide a prognostic marker and therapeutic target of EC.
|
31527078 |
2019 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results support the notion that the PI3K signaling pathway might be activated, both dependent- and independently of PIK3CA mutations, an aspect that should be considered when designing PIK3 pathway targeting strategies in endometrial cancer.
|
28860563 |
2017 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we elucidated the involvement of the up-regulation of RAS/MAPK and PI3K/AKT cascades in the pathogenesis of endometrial cancer and melanoma by analyzing the genes and molecules in these cascades.
|
16273242 |
2005 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI3K/mammalian target of rapamycin (mTOR) pathway aberrations occur in 40% to 80% of endometrial cancer.
|
24651628 |
2014 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results affirm the utility of systematic characterization of the cancer genome in clinically annotated specimens and suggest the particular importance of the PI3K pathway in patients who have aggressive endometrial cancer.
|
19261849 |
2009 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Robust growth suppression by NVP-BEZ235 suggests that a dual PI3K/mTOR inhibitor is a promising therapeutic for endometrial carcinomas.
|
22662154 |
2012 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Taken together, our results showed that the formulation of BSYX had antitumor effect on endometrial cancer in vivo and in vitro and was related with FSH/PI3K/AKT/Gankyrin/HIF-<i>α</i>/cyclinD1 transduction pathway.
|
30402135 |
2018 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although molecular characterization has been reported to customize therapeutic strategies and thereby improve therapeutic outcomes in EC, none of the targeted agents investigated (antiangiogenic and mTOR/PI3K pathway inhibitor agents) have resulted in a change in clinical practice in HR-EC.
|
31176047 |
2019 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-101 reduces cell proliferation and invasion and enhances apoptosis in endometrial cancer via regulating PI3K/Akt/mTOR.
|
29081412 |
2017 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings support the de-regulation of the PI3K/Akt/mTOR and MAPK signaling pathways in type I endometrial carcinomas suggesting involvement of these pivotal pathways in endometrial carcinogenesis.
|
25862896 |
2015 |
|
Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In breast, colon, and endometrial cancers in which the PI3K pathway is activated by a combination of mutant PIK3CA and alterations in Ras, ERBB2/3, or PTEN, signaling to downstream elements such as Akt was mediated exclusively by the p110alpha isoform, rather than a combination of different PI3K isoforms.
|
18829572 |
2008 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We observed that the clinical behaviour of endometrial cancers as a group was associated with hormone receptor signalling, PI3K pathway signalling and DNA mismatch repair processes.
|
27420608 |
2016 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deregulated signaling via the phosphatidylinositol 3-kinase (PI3K) pathway is common in many types of cancer, but its clinicopathological significance in endometrial cancer remains unclear.
|
17924977 |
2007 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We searched for alterations in the catalytic domain of PI3K (PIK3CA), PTEN and KRAS, all of which may contribute to PI3K/AKT pathway activation, in a total of 160-familial colorectal (CRC) and endometrial carcinomas (EC), stratified by the presence vs. absence of germline mutations in DNA mismatch repair (MMR) genes.
|
17471559 |
2007 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activation of the PI3K pathway is seen in more than 90% of FGFR2<sup>mutant</sup> endometrial cancers.
|
28119489 |
2017 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The PTEN tumor suppressor gene is frequently mutated in type I endometrial cancers and this mutation results in hyperactivation of the PI3K/AKT pathway.
|
22911820 |
2012 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nuclear estrogen receptor-mediated Notch signaling and GPR30-mediated PI3K/AKT signaling in the regulation of endometrial cancer cell proliferation.
|
22075757 |
2012 |
|
Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Importantly, through western blot analysis, we found that inhibition of CLDN6 remarkably decreased p-AKT, p-PI3K, and mTOR expression level in EC HEC-1B cell line.
|
30319275 |
2018 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The goal of this study was to determine whether PIK3R1, which encodes p85α, the inhibitory subunit of PI3K, is mutated in endometrial carcinoma.
|
21478295 |
2011 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We attempt to investigate the effect of metformin on Ki-67, PI3K, p-AKT, p-S6K1, and p-4EBP1 staining in human endometrial cancer by immunohistochemical staining.
|
29182407 |
2018 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression profiling of 22 genes involved in PI3K-AKT signaling pathway was analyzed in 38 endometrial carcinomas using TaqMan low-density array (TLDA) analysis.
|
20173732 |
2010 |